EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome
Medicine should no longer be used for other disorders of the gut
A review by the European Medicines Agency (EMA) has concluded that Symbioflor 2 and associated names can continue to be used for treatment of irritable bowel syndrome (IBS) in adults. However, the medicine should no longer be used more widely to treat so-called functional gastrointestinal disorders, a group of disorders with a variety of causes that may require different treatment approaches.
Symbioflor 2, which contains Escherichia coli bacteria, has been described as a probiotic, which means that it encourages the growth of beneficial organisms (‘flora’) in the gut. It was first made available in Germany in the 1950s and subsequently in Austria and Hungary.
In reaching its conclusions, EMA’s Committee for Medicinal Products for Human Use(CHMP) reviewed all available evidence on the effectiveness and safety of Symbioflor 2. The data included clinical studies, scientific publications, post-marketing experience, as well as information provided by the company and the views of an expert group formed for evaluating Symbioflor 2. The review did not find any new evidence on the effectiveness of Symbioflor 2 since the product was last approved. Available evidence suggests that the risk of harm from Symbioflor 2 is low.
A randomised study involving around 300 adults suggested that Symbioflor 2 was effective for treating IBS. However, the study had weaknesses. Benefit has not yet been established in children with IBS.
Since the available data are not sufficiently robust for the CHMP to draw conclusions on how well Symbioflor 2 works and whether it is effective for any particular type of IBS, the CHMP has asked the company to carry out a well-designed study on effectiveness and safety among patients with different features of IBS (e.g. those with diarrhoea or with constipation as an important feature). Submission of the study report to national authorities will be a condition for maintaining Symbioflor 2’s marketing authorisation.
The company that markets Symbioflor 2 did not submit data to support its use in ‘functional gastrointestinal disorders’ and agreed to remove this use from the medicine’s authorisation.
The CHMP recommendation will now be sent to the European Commission for a legally binding decision that will be valid throughout the EU.
|EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome||(English only)||23/06/2017|
Latest News from
Statement by Executive Vice-President Margrethe Vestager on the Commission's decision to appeal the General Court's judgment on the Apple tax State aid case in Ireland25/09/2020 15:25:00
Statement given by Executive Vice-President Margrethe Vestager on the Commission's decision to appeal the General Court's judgment on the Apple tax State aid case in Ireland.
Why is Parliament calling for new EU revenue-raising powers?25/09/2020 14:33:00
Parliament is calling for new EU revenue sources to invest in Europe’s future and support the Covid-19 recovery without burdening taxpayers.
Hong Kong: Statement by the Spokesperson on the arrest of Joshua Wong and other pro-democracy activists25/09/2020 13:25:00
The arrest of Hong Kong pro-democracy activist Joshua Wong on 24 September is the latest in a troubling series of arrests of pro-democracy activists since the summer.
ESMA Consults On MIFIR Reference Data And Transaction Reporting25/09/2020 12:38:00
The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, yesterday launched a Consultation Paper (CP) reviewing the reference data and transaction reporting obligations under the Market in Financial Instruments Regulation (MiFIR).
MEPs question whether the new Migration Pact will bring about real change25/09/2020 11:33:00
The new Migration Pact is insufficient for the majority of EP groups. Some demand compulsory relocation of refugees; others want a firmer stance on irregular arrivals.
Questions and Answers: Coronavirus and the EU Vaccines Strategy25/09/2020 09:25:00
On 17 June, the European Commission presented a European strategy to accelerate the development, manufacturing and deployment of vaccines against COVID-19.
European Centre for Disease Prevention and Control's new risk assessment shows need to step up coronavirus response in the EU24/09/2020 17:02:00
Today, the European Centre for Disease Prevention and Control (ECDC) published its updated risk assessment regarding the COVID-19 pandemic, alongside a set of guidelines for non-pharmaceutical interventions (such as hand hygiene, physical distancing, cleaning and ventilation).
Artificial intelligence: threats and opportunities24/09/2020 16:33:00
Artificial intelligence (AI) affects our lives more and more. Learn about the opportunities and threats for security, democracy, businesses and jobs.
Tourism Committee MEPs: EU must act, 22 million jobs are at stake24/09/2020 15:25:00
Members of Parliament’s Tourism Task Force reiterate that the tourism sector needs EU-level coordination and substantial support to give SMEs a chance of survival.